No annual revenue total was found in Tevogen Inc.'s SEC filings.
Tevogen Inc. (TVGN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$12.4 million. As of Jun 30, 2026 it held $1.1 million in cash and investments and $1.4 million in total debt.
Revenue
—
Net income (TTM)
$-21.61M
+30.7% vs year-ago TTM
Operating cash flow (TTM)
$-11.57M
+13.3% vs year-ago TTM
Free cash flow
$-12.39M
-49.2% vs prior year
EPS (TTM)
$-6.32
-1489.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.19M
+0.6% vs prior year
Net cash
$-309,677
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TVGN (Nasdaq), TVGNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860871
- Former names
- Tevogen Bio Holdings Inc. (until Jul 30, 2026); Semper Paratus Acquisition Corp (until Feb 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$26.1M | -$53.6M | — | — |
| Net income | -$26.3M | -$13.7M | -$60.5M | $4.4M |
| Diluted EPS | -$8.08 | -$3.50 | — | — |
| Operating cash flow | -$12.3M | -$12.0M | -$8.2M | -$215,395 |
| Free cash flow | -$12.4M | — | -$8.3M | — |
| Total assets | $4.4M | $3.5M | $5.5M | $357.1M |
| Total liabilities | $12.6M | $10.1M | $99.9M | $15.1M |
| Stockholders' equity | -$8.2M | -$6.7M | -$94.4M | -$34.0M |
| Cash and investments | $0 | $0 | — | $129,186 |
| Total debt | $1.5M | $234,859 | — | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change
|
Nov 3, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Aug 26, 2026 | Aug 24, 2026 |
All 309 Tevogen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.